Darryl Sleep

Senior Vice President, Head of Clinical Science and Asset Strategy for the Cardiovascular and Metabolic Therapeutic Area Unit With extensive global clinical and industry experience across multiple therapeutic areas Darryl Sleep, M.D. is Senior Vice President, Head of Clinical Science and Asset Strategy for the Cardiovascular and Metabolic (CVM) Therapeutic Area Unit (TAU) at Takeda Pharmaceuticals.  He leads the clinical science group as well as the program leaders within the CVM TAU that covers a wide pipeline portfolio including programs in the cardiovascular, diabetes, obesity, renal, and respiratory areas. Dr. Sleep joined Takeda in 2010 as Vice President Clinical Science and Therapeutic Area Clinical Head for Cardiovascular, GU and Renal, where he oversaw the development strategy and clinical programs within these therapeutic areas. In 2011, Dr. Sleep was appointed Head of the Biological Sciences and transformed the group into Exploratory & Translational Development responsible for the translation of Takeda’s pipeline from pre-clinical to early clinical development, working with both the research and development functions to establish proof of mechanism and proof of concept for drugs in development. In November 2012 Dr. Sleep was appointed Head of Clinical Science and Early Development in TDC Americas, integrating the clinical group from Exploratory & Translational Development into Clinical Science. Dr. Sleep was appointed as the Global Head of Clinical Scienc...
Source: PHRMA - Category: Pharmaceuticals Authors: Source Type: news